MediWound Ltd. Aktie News

Unabhängiges DSMB empfiehlt Fortführung von MediWound's EscharEx® Phase III VALUE-Studie ohne Änderungen. Das DSMB identifizierte in der vorgegebenen Überprüfung keine Sicherheitsbedenken; die Zwischenbewertung und der Abschluss der Einschreibungen bleiben bis Ende des ersten Quartals 2027 im Zeitplan. YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), ein globa...

EscharEx® Phase‑III‑VALUE‑Studie schreitet voran; Zwischenbewertung und Abschluss der Einschreibung bis Ende des ersten Quartals 2027 erwartet Rahmenleistungsvertrag mit Vericel im Rahmen des BARDA‑Vertrags für NexoBrid® unterzeichnet Umsatz im zweiten Quartal 3,1 Mio. USD; Umsatzprognose für das Gesamtjahr 2026 in Höhe von 24–26 Mio. USD bekräftigt Telefonkonferenz heute um 8:30 a.m. Eastern T...

EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd.

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing Panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx ® in chronic wound ca...

MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences   Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel, April 7, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation en...

MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year con...